Apoptosis: targets in pancreatic cancer

Mol Cancer. 2003 Jan 7:2:6. doi: 10.1186/1476-4598-2-6.

Abstract

Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / physiopathology
  • Adenocarcinoma / therapy
  • Apoptosis / physiology*
  • Growth Substances / physiology
  • Humans
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins / physiology
  • Neoplasm Proteins
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / physiopathology*
  • Proto-Oncogene Proteins c-bcl-2 / physiology
  • Receptors, Tumor Necrosis Factor / physiology
  • Signal Transduction
  • Survivin
  • Tumor Suppressor Protein p53 / physiology

Substances

  • BIRC5 protein, human
  • Growth Substances
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Tumor Necrosis Factor
  • Survivin
  • Tumor Suppressor Protein p53